A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

A Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

The study will assess the efficacy of OC000459 200 mg twice daily orally in comparison to placebo when subjects are challenged in the Vienna Challenge Chamber for 6 hours. This is a randomised, double blind, placebo controlled, two way crossover evaluation. There will be a screening period of up to three weeks and a washout period of at least one week between the two treatment periods. There will be a follow up one to three weeks after the last dose of study drug.

Inclusion Criteria:

• Males aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years.
• Subjects must be free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and screening investigations.
• FEV1 within normal limits (≥90% of predicted).
• Atopy defined by a positive cutaneous response to mixed grass pollen within the last 12 months or at screening.
• Asymptomatic at screening
• Non smokers for at least the past 12 months

Exclusion Criteria:

• Medical conditions likely to affect the outcome of the study.
• Nasal conditions likely to affect the outcome of the study, i.e. nasal septal perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal diseases.
• Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function
• Immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days.